Entrada Therapeutics (TRDA) Non-Current Deffered Revenue (2021)
Entrada Therapeutics (TRDA) recorded quarterly Non-Current Deffered Revenue of $396000.0 in Q4 2021, up 16.81% quarter-over-quarter from $339000.0 in Q3 2021.
Entrada Therapeutics (TRDA) Non-Current Deffered Revenue (2021) Analysis & Trends
Entrada Therapeutics' Non-Current Deffered Revenue history runs 1 years deep, the most recent figure standing at $396000.0 for Q4 2021.
- In Q4 2021, Non-Current Deffered Revenue changed N/A year-over-year to $396000.0; the TTM figure through Dec 2021 stood at $396000.0 (changed N/A YoY), while the FY2021 annual figure was $396000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue was $396000.0 for Q4 2021 at Entrada Therapeutics, up from $339000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $396000.0 in Q4 2021 to a low of $339000.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Entrada Therapeutics | 295.36 Mn | 295.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 396,000.00 |
| Sep 30, 2021 | 339,000.00 |